All News
Making You the Expert of You! (Smart Rules for Patients)
You’ve scheduled an appointment with your medical provider - how do you make the most of it? We've gathered these tips and suggestions to share with patients.
Read Article
Polygenic Risk Scores to Identfy Severe Knee and Hip Osteoarthritis
Prevention of knee and hip osteoarthritis would obviate considerable disability and future surgery. We may be one step closer according to a prospective European GWAS study showing polygenic risk scores (PRSs) significantly associated with higher risks for knee and hip OA joint replacement.
Read Article
Diagnostic Delays in Spondyloarthritis Still Prolonged
Previously quoted average delay in diagnosing axial spondyloarthritis (axSpA) may be improving as a recent UK study shows the mean average time to diagnosis in two different NHS trusts was between five and six years.
Read Article
Comparison of NHANES survey data from 2 eras (2007–2008 and 2017–2018) shows that prevalence blood pressure control decreased from 65% to 55% over 10 yrs(P=0.03); while lipid control remained stable; and diabetes med use rose 71% to 95% https://t.co/WIWBCYo2Yi https://t.co/mS7uVIiyUq
Links:
Dr. John Cush RheumNow ( View Tweet)
Prophylaxis against pneumocystis pneumonia in RA patients treated with b/tsDMARDs: insights from 3787 cases in the FIRST registry https://t.co/zeDQpP1NEH proph reduced PCP by 3/1000 per yr, 5 pts PCP despite proph, 80% on MTX & 11% cease proph due to AEs!
Peter Nash drpnash ( View Tweet)
Small RCT 39 pts with #PMR given tocilizumab or placebo. Steroid-free remission at wk 16 was 64% on tocilizumab (63.2%) and 12% placebo. Mean time to first relapse was shorter with PBO (82 vs 130days). 5 SAE PBO, 1 TCZ https://t.co/5tomZsaaU6 https://t.co/yAMGY5nlCU
Links:
Dr. John Cush RheumNow ( View Tweet)
Evobrutinib, selective oral BTK inhibitor, has been studied in >1083 pts in phase 3 RCTs of RA, SLE, MS; shows well tolerated, most common AE ≥5% UTI (9.5%), nasopharyngitis (7.3%), diarrhea (6.2%), transient ^LFTs, SIE rate 2.72/100 PYs https://t.co/NTKYOAHhln https://t.co/oUKCDicjyA
Links:
Dr. John Cush RheumNow ( View Tweet)
Acne with JAK Inhibitors
JAK inhibitors have become enormously popular and while their side effect profile has been delineated and reviewed, little mention is made of acne – an adverse event that may affect up to one-quarter of patients taking JAKi.
https://t.co/b9pX9NgZAx https://t.co/RL9vi3Xbf6
Links:
Dr. John Cush RheumNow ( View Tweet)
Prospective randomized trial of ultrasound-guided genicular nerve block (GNB) vs physical therapy (PT) i102 pts chronic knee #OA - GNB was superior at walk distance, pain, functional and physical capacity, at 12 weeks https://t.co/MOJ16zAiqH https://t.co/JJJye2dobH
Links:
Dr. John Cush RheumNow ( View Tweet)
Expansive (full read) review of CBD - legal and regulatory overview, availability, physiologic and pharmacologic effects, safety, & risks, standards, use in specific rheumatic disorders. https://t.co/hefwKTmPLK https://t.co/IZKZMOZ5ij
Links:
Dr. John Cush RheumNow ( View Tweet)
TOMORROW! Register for our 5/10 Tuesday Night Rheumatology on PsA Advances.
This webinar will feature highlights from:
PsA Guidelines
Arthur Kavanaugh, MD
Drug Targeting in PsA
Bruce Kirkham, MD
PsA Registries and Real World Data
Alexis Ogdie, MD
https://t.co/0fNuHz6wVy https://t.co/KssNJ41Wqz
Links:
Dr. John Cush RheumNow ( View Tweet)
DOCTORS: are you ready to attend big medical meetings ? @LCalabreseDO
Dr. John Cush RheumNow ( View Tweet)
Allopurinol Use Does Not Increase Mortality in Gout w/ Chronic Kidney Disease
A trial has shown that allopurinol use dose escalation and achieving target uric acid levels, was not associated w/ increased mortality in patients with gout and concurrent CKD.
https://t.co/8LHlRyTgS0 https://t.co/4Hu9cTwptO
Links:
Dr. John Cush RheumNow ( View Tweet)
Hyperuricemia as a biomarker of severe #PsA? Study of 242 PsA pts 30% had hyperuricemia & 6% had gout. Hyperuricemia was significantly associated with age, comorbidity, perph polyarthritis, Jt destruction, less response to treatment. https://t.co/U5wAQdWLdC https://t.co/QfoaogDeun
Links:
Dr. John Cush RheumNow ( View Tweet)
TLR7 signaling impt to SLE as it drives type I IFN & activation of autoreactive B cells. Nature reports missense TLR7 (Y264H) variant from severe lupus induces guanosine & cGMP & causes murine lupus when introduced into mice. https://t.co/VZioZfcJQ6 https://t.co/AtxWD4XGBF
Dr. John Cush RheumNow ( View Tweet)
Good free patient info handout on LUMBAR SPINAL STENOSIS from JAMA https://t.co/aDPwLzFvfQ
Links:
Dr. John Cush RheumNow ( View Tweet)
Phase 2b DBRPCT of Intranodular injections of adalimumab in 140 pts w/ Dupuytrens contracture showed signif reduction nodule size and hardness ((−4·6 vs −2·2; p=0·0002) at 12 months https://t.co/9wBOeQNUdL https://t.co/HOR8rzYuRa
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Judith James on environmental factors that contribute to lupus risk and expression. #UTSWSLE2022 https://t.co/MGE51vlDMY
Dr. John Cush RheumNow ( View Tweet)
GALAXI-1 Study - Guselkumab effective in Crohn's Disease. 309 CD pts (1/2 refractory dz) Rx w/ either PBO, or IV GUS 200 mg, 600 mg, or 1200 mg at weeks 0, 4, and 8; At week 12, all 3 doses had signif. clinical and endoscopic improvements vs PBO https://t.co/iGyAmCoO96
Links:
Dr. John Cush RheumNow ( View Tweet)
RBCs from SLE patients retain mitochondrial proteins that may either lead to type I IFN or be taken up by myeloid cells. (V. Pascual) #UTSWSLE2022 https://t.co/VdQGRDUMvX
Dr. John Cush RheumNow ( View Tweet)